- Home
- GSRT vs VNDA Comparison
GSRT vs VNDA Comparison
Compare GSRT & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSRT
- VNDA
- Stock Information
- Founded
- GSRT 2023
- VNDA 2002
- Country
- GSRT United States
- VNDA United States
- Employees
- GSRT N/A
- VNDA N/A
- Industry
- GSRT
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- GSRT
- VNDA Health Care
- Exchange
- GSRT Nasdaq
- VNDA Nasdaq
- Market Cap
- GSRT 302.5M
- VNDA 249.4M
- IPO Year
- GSRT 2024
- VNDA 2006
- Fundamental
- Price
- GSRT $10.35
- VNDA $4.61
- Analyst Decision
- GSRT Strong Buy
- VNDA Strong Buy
- Analyst Count
- GSRT 1
- VNDA 2
- Target Price
- GSRT $19.00
- VNDA $16.50
- AVG Volume (30 Days)
- GSRT 466.9K
- VNDA 460.3K
- Earning Date
- GSRT 01-01-0001
- VNDA 11-05-2025
- Dividend Yield
- GSRT N/A
- VNDA N/A
- EPS Growth
- GSRT N/A
- VNDA N/A
- EPS
- GSRT 0.19
- VNDA N/A
- Revenue
- GSRT N/A
- VNDA $203,467,000.00
- Revenue This Year
- GSRT N/A
- VNDA $15.45
- Revenue Next Year
- GSRT N/A
- VNDA $37.82
- P/E Ratio
- GSRT $53.35
- VNDA N/A
- Revenue Growth
- GSRT N/A
- VNDA 11.78
- 52 Week Low
- GSRT $9.86
- VNDA $3.81
- 52 Week High
- GSRT $11.49
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- GSRT 39.11
- VNDA 51.38
- Support Level
- GSRT $10.35
- VNDA $4.54
- Resistance Level
- GSRT $10.40
- VNDA $4.92
- Average True Range (ATR)
- GSRT 0.05
- VNDA 0.19
- MACD
- GSRT 0.01
- VNDA 0.02
- Stochastic Oscillator
- GSRT 13.33
- VNDA 38.00
About GSRT GSR III Acquisition Corp. Ordinary Shares
GSR III Acquisition Corp is a blank check company.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.